Exact Sciences Corp
EXAS
查看详细走势图
103.180USD
+0.520+0.51%
收盘 02/06, 16:00（美东）报价延迟15分钟
19.55B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.51%
5天
+0.82%
1月
+1.51%
6月
+119.95%
今年开始到现在
+1.60%
1年
+90.09%
查看详细走势图
TradingKey Exact Sciences Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Exact Sciences Corp当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名72/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价101.83。中期看，股价处于上升通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Exact Sciences Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Exact Sciences Corp亮点
亮点风险
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
业绩高增长
公司营业收入稳步增长，连续3年增长32.37%
利润高增长
公司净利润处于行业前列，最新年度总收入2.76B美元
估值合理
公司最新PE估值-19.32，处于3年历史合理位
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值2.35K
活跃度增加
近期活跃度增加，过去20天平均换手率0.52
分析师目标
根据
23
位分析师
持有
评级
101.833
目标均价
-0.81%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Exact Sciences Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Exact Sciences Corp简介
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
公司代码EXAS
公司Exact Sciences Corp
CEOConroy (Kevin T)
网址https://www.exactsciences.com/
相关品种
